Background Hybrid coronary revascularization （HCR） is an altemative coronary revascularization strategy that combines a minimally invasive, survival advantage of the left internal mammary artery （LIMA） -left anter...Background Hybrid coronary revascularization （HCR） is an altemative coronary revascularization strategy that combines a minimally invasive, survival advantage of the left internal mammary artery （LIMA） -left anterior descending （LAD） coronary artery bypass with less-invasive percutaneous coronary intervention （PCI） to non-LAD coronary lesions by using drug-eluting stents. We report our experience of hybrid minimally invasive approach in 15 patients. Methods From December 2012 to October 2013, 15 patients underwent revascularization of the left anterior descending artery through minimally invasive coronary artery bypass grafting （MIDCAB）. All patients by endoscopic assist beating heart coronary artery bypass grafting. Seven patients were scheduled for a hybrid procedure. Percutaneous coronary intervention of non- LAD was performed 3 to 5 days preoperatively. Demographic data, perioperative outcome, and annual follow-up were obtained from all the patients. Results In-hospital mortality was 6.67%. The rate of conversion to full median sternotomy was 13.3%. Ventilation time was 6.9 ± 5.1 h. Blood loss volume was 241 ± 67.8 mL. ICU stay was 21.3 ± 10.8 h. Hospital postoperative stay lasted for 7.5 ± 1.3 days. Prior to PCI patients showed 100% patent LIMA （Tables 3 and 4）. A mean follow-up was 8.5 months. One year graft patency rate was 100% （8/8 patients for 254-slice tomography）. Two patients required reintervention. Conclusions Minimally invasive hybrid coronary revascularization is a safe, feasible and efficacious approach with good results and should be performed in selected patients by surgeons with experience in minimally invasive bypass surgery plus collaboration with cardiologists, eluting stents.展开更多
目的:比较一站式复合再血管化技术与非体外循环下冠状动脉旁路移植术(OPCABG)治疗冠状动脉多支病变的术后30天预后结果,探讨一站式复合再血管化技术临床应用安全性及有效性。方法:2009-01至2017-01,在阜外医院接受一站式复合再血管化治...目的:比较一站式复合再血管化技术与非体外循环下冠状动脉旁路移植术(OPCABG)治疗冠状动脉多支病变的术后30天预后结果,探讨一站式复合再血管化技术临床应用安全性及有效性。方法:2009-01至2017-01,在阜外医院接受一站式复合再血管化治疗的冠状动脉多支病变患者共533例(一站式复合技术组)。应用倾向性评分法,筛选同期533例OPCABG患者(OPCABG组)与一站式复合技术组患者进行1:1配对。主要终点事件为术后30天主要不良心脑血管事件(MACCE);次要终点为术后住院结果,包括术后胸管总引流量,血制品使用率,术后呼吸机使用时间、重症监护室(ICU)停留时间等。结果:与OPCABG组相比,一站式复合技术组术后胸管总引流量[714(523,971)ml vs 965(716,1 220)ml,P<0.001]显著减少,降低了血制品使用率(19.7%vs 34.0%,P=0.024),缩短了呼吸机使用时间[12.6(9.3,15.7)h vs16.0(12.8,18.7)h,P<0.001]和ICU停留时间[21.7(19.8,42.4)h vs 41.6(23.6,70.0)h,P<0.001];术后30天全因死亡率、心肌梗死、脑血管事件、再血管化事件及总体MACCE发生率差异均无统计学意义。结论:对于冠状动脉多支病变患者,一站式复合再血管化技术提供了另一种安全、有效的治疗选择;与OPCABG相比,创伤减少,早期治疗效果相似。展开更多
文摘Background Hybrid coronary revascularization （HCR） is an altemative coronary revascularization strategy that combines a minimally invasive, survival advantage of the left internal mammary artery （LIMA） -left anterior descending （LAD） coronary artery bypass with less-invasive percutaneous coronary intervention （PCI） to non-LAD coronary lesions by using drug-eluting stents. We report our experience of hybrid minimally invasive approach in 15 patients. Methods From December 2012 to October 2013, 15 patients underwent revascularization of the left anterior descending artery through minimally invasive coronary artery bypass grafting （MIDCAB）. All patients by endoscopic assist beating heart coronary artery bypass grafting. Seven patients were scheduled for a hybrid procedure. Percutaneous coronary intervention of non- LAD was performed 3 to 5 days preoperatively. Demographic data, perioperative outcome, and annual follow-up were obtained from all the patients. Results In-hospital mortality was 6.67%. The rate of conversion to full median sternotomy was 13.3%. Ventilation time was 6.9 ± 5.1 h. Blood loss volume was 241 ± 67.8 mL. ICU stay was 21.3 ± 10.8 h. Hospital postoperative stay lasted for 7.5 ± 1.3 days. Prior to PCI patients showed 100% patent LIMA （Tables 3 and 4）. A mean follow-up was 8.5 months. One year graft patency rate was 100% （8/8 patients for 254-slice tomography）. Two patients required reintervention. Conclusions Minimally invasive hybrid coronary revascularization is a safe, feasible and efficacious approach with good results and should be performed in selected patients by surgeons with experience in minimally invasive bypass surgery plus collaboration with cardiologists, eluting stents.
文摘目的:比较一站式复合再血管化技术与非体外循环下冠状动脉旁路移植术(OPCABG)治疗冠状动脉多支病变的术后30天预后结果,探讨一站式复合再血管化技术临床应用安全性及有效性。方法:2009-01至2017-01,在阜外医院接受一站式复合再血管化治疗的冠状动脉多支病变患者共533例(一站式复合技术组)。应用倾向性评分法,筛选同期533例OPCABG患者(OPCABG组)与一站式复合技术组患者进行1:1配对。主要终点事件为术后30天主要不良心脑血管事件(MACCE);次要终点为术后住院结果,包括术后胸管总引流量,血制品使用率,术后呼吸机使用时间、重症监护室(ICU)停留时间等。结果:与OPCABG组相比,一站式复合技术组术后胸管总引流量[714(523,971)ml vs 965(716,1 220)ml,P<0.001]显著减少,降低了血制品使用率(19.7%vs 34.0%,P=0.024),缩短了呼吸机使用时间[12.6(9.3,15.7)h vs16.0(12.8,18.7)h,P<0.001]和ICU停留时间[21.7(19.8,42.4)h vs 41.6(23.6,70.0)h,P<0.001];术后30天全因死亡率、心肌梗死、脑血管事件、再血管化事件及总体MACCE发生率差异均无统计学意义。结论:对于冠状动脉多支病变患者,一站式复合再血管化技术提供了另一种安全、有效的治疗选择;与OPCABG相比,创伤减少,早期治疗效果相似。
